Synthace secures £26m Series C funding co-led by Horizons Ventures and Sofinnova Partners to drive commercial expansion.
The life sciences software provider raised the capital from Horizons Ventures and Sofinnova Partners to fund commercial growth.
Synthace operates a cloud platform that helps life sciences organisations automate biology experimentation and share insights. Seven of the top ten global pharmaceutical companies use its software.
London-based life sciences software provider Synthace has secured £26m in a Series C funding round. The investment was co-led by Horizons Ventures and Sofinnova Partners.
The capital will be directed towards commercial expansion and go-to-market growth, alongside the recruitment of senior U.S. leadership. This follows strong recent momentum for the company, which has seen increased adoption of its R&D cloud platform among major pharmaceutical firms.
From the founder
"But to maximize impact, we need to expand access and reach to customers across the globe—at scale. This investment serves as a strong vote of confidence from world-class investors in the biopharmaceutical and innovation technology industries. With their support, we’ll be able to better deploy human and financial capital to help transform scientific dreams into drugs and alternative food sources."
Guy Levy-Yurista
CEO at Synthace
Investor perspective
"Building on our decades of experience funding innovative life science companies, we’re thrilled to partner with Synthace and help unlock the potential of this ambitious, high-growth company."
Thomas Burt
Partner, Sofinnova Partners
Use of funds
- 01Accelerate go-to-market
